‘Hijacker’ Drives Cancer in Some Patients with High-Risk Neuroblastoma
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome “hijacks” DNA that regulates other genes. The resulting insights may help scientists develop more effective therapies, including precision medicines.
The research involved investigators at St. Jude Children’s Research Hospital; Dana-Farber Cancer Institute, Boston; and the Whitehead Institute for Biomedical Research, Cambridge, Massachusetts.
Neuroblastoma is a cancer of the sympathetic nervous system diagnosed annually in about 800 U.S. residents, primarily infants and young children. Although the long-term survival rate for patients with low-risk neuroblastoma is about 95 percent, the prognosis is worse for the 40 percent of patients with high-risk neuroblastoma. About half of those patients are alive five years after diagnosis.
Click here to read more.
CARS 2018 Computer Assisted Radiology and Surgery
June 20-23, 2018; Berlin, Germany
2018 New England Neurosurgical Society Annual Meeting
June 28-30, 2018; Chatham, MA
15th International Congress on Neuromuscular Diseases
July 6-10, 2018; Vienna
International Summer School Transnasal Endoscopic Surgery: From Sinuses to Skull Base
July 9-13, 2018; Brescia, Italy
7th Annual World Course in Advanced Brain Tumor Surgery
July 12-15, 2018; London